Capitulo 1

Capitulo 2

Capitulo 3

Capitulo 4

Capitulo 5

Capitulo 6

Capitulo 7

Capitulo 8

Capítulo 3: Dislipidemia

• Austin MA, Edwards KL Curr Opin Lipidol 1996; 7:167-171; Austin MA y cols. JAMA 1988; 260:1917-1921.
• Sniderman AD et al Diabetes Care 2002; 25:579-582.
• Reaven GM, et al. J Clin Invest. 1993; 92:141-146.
  Ebri Torne B, Ebri Verde MI, Portoles Suso A, Fuentes Solsona F, Perez Conesa M, Cuende Melero JI, Grupo de Estudio Cifarc Grupo de Riesgo Vascular de la Semi.
• [Differences in variables representative of cardiovascular disease or repercussion between subjects with high cardiovascular risk with and without any family history of early cardiovascular events.]An. Med Interna. 2006 Jan; 23(1):11-8. PMID: 16542116 [PubMed - in process].
• Rizzo M, Berneis K, Corrado E, Novo S. The significance of low-density-lipoproteins size in vascular diseases. Int Angiol. 2006 Mar; 25(1):4-9. PMID: 16520717 [PubMed - in process].
• Todd J, Farmer JA. Optimal low-density lipoprotein levels: Evidence from epidemiology and clinical trials. Curr Atheroscler Rep. 2006 Mar; 8(2):157-62. PMID: 16510050 [PubMed - in process].
• Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular prevention. Eur J. Intern Med. 2006 Mar; 17(2):77-80. PMID: 16490681 [PubMed - in process].
• NCEP REPORT: Scott M. Grundy, James I. Cleeman, C. Noel Bairey Merz, H. Bryan Brewer, Jr, Luther T. Clark, Donald B. Hunninghake, Richard C. Pasternak, Sidney C. Smith, Jr, Neil J. Stone, for the Coordinating Committee of the National Cholesterol Education Program Endorsed by the National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, and American Heart Association.
  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Circulation, Jul 2004; 110:227-239.
• Grundy SM, Cleeman JI, Merz CN, et al, for the Coordinating Committee of the National Cholesterol Education Program. Endorsed by the National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; and American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110:227-239.
• St-Pierre AC, Cantin B, Dagenais GR, et al. Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men. Am J Cardiol 2006; 97:997-1001.
• Jungner I, Sniderman AD, Furberg C, et al. Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction. Am J. Cardiol 2006; 97:943-946.
• Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet 2001; 358:2026-33.
• Zimmermann TS, Lee AC, Akinc A. RNAi-mediated gene silencing in nonhuman primates. Nature 2006; DOI: 10.1038/nature 04688. Available at: http://www.nature.com.